A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma

Inclusion Criteria: 1. patients underwent liver tumor resection and pathological diagnosis of HCC in our hospital. 2. The tumor samples of these HCC patients were detected by in situ hybridization with miR-145, miR-31 and miR-92a. We used the previously established HCC lymph node metastasis microRNA prediction model to determine the patients with high-risk lymph node metastasis and low-risk patients at high risk Patients were randomly assigned into treatment group and control group with informed consent. 3. HCC patients were not receive other anti-cancer treatment. 4. Blood routine examination was normal. 5. Child-Pugh grade A, normal liver and kidney function in the normal range (including ALT or ASL within 2.5 times the normal), WBC\> 3 × 109 / L, Hb\> 90g / L, PLT\> 50 × 109 / 6. HCC patients were not receive the history of upper abdominal radiotherapy. 7. sign the informed consent. 8. age 18-75 years old. 9. KPS score 80-100 points. Exclusion Criteria: 1. accepted other anti-cancer treatment. 2. Patients was determined to be low-risk lymph node metastasis by the pre-established HCC lymph node metastasis microRNA prediction model. 3. blood and liver and kidney dysfunction. 4. can not control the infection. 5. at the same time the merger of other malignant tumors. 6. while using other experimental drugs or to participate in other clinical trials. 7. serious heart, lung, kidney disease. 8. pregnant or lactating women. 9. serious nervous system disease, can not clearly tell the treatment